Johnson & Johnson (NYSE:JNJ) is scheduled to release its quarterly earnings report tomorrow, and as a huge health-care conglomerate with a strong presence in consumer health-care products, medical devices, and pharmaceuticals, the company has drawn investors’ interest throughout 2013, gaining about 30% year to date. Even as its competitors — including some of its compatriots among the Dow Jones Industrials — have looked to break themselves into smaller parts, J&J has thus far held itself together as a giant in the industry.
As Johnson & Johnson (NYSE:JNJ)’s share price has risen, though, so too have concerns that the company’s stock may be getting ahead of its fundamental growth prospects. With economic challenges facing the company throughout the world, can it produce enough earnings growth to make investors happy? Let’s take an early look at what’s been happening with Johnson & Johnson over the past quarter and what we’re likely to see in its quarterly report.
Stats on Johnson & Johnson
|Analyst EPS Estimate||$1.39|
|Change From Year-Ago EPS||6.9%|
|Revenue Estimate||$17.71 billion|
|Change From Year-Ago Revenue||7.5%|
|Earnings Beats in Past 4 Quarters||4|
How can Johnson & Johnson make its earnings grow faster?
Analysts have grown somewhat more optimistic about Johnson & Johnson (NYSE:JNJ)’s earnings prospects in recent months, keeping their quarterly estimates stable but adding a penny per share to their full-year 2013 estimates and $0.02 per share to next year’s earnings consensus. The stock has continued its run, rising more than 10% since early April.
J&J has plenty of things going for it to justify shareholders’ enthusiasm about the stock. The company has strong brands across its three major segments, and it’s one of few companies that have maintained a triple-“A” bond rating.
In particular, J&J’s pharmaceuticals division has shown a lot of potential lately. The pharma giant had its Invokana treatment for type 2 diabetes approved in late March, and Johnson & Johnson (NYSE:JNJ) hopes it will be able to knock Merck & Co., Inc. (NYSE:MRK)‘s Januvia off its pedestal in the diabetes space. Studies showed Invokana to be superior to Januvia, and if current long-term safety trials confirm the drug’s safety and effectiveness, then it could seriously diminish Januvia’s blockbuster-sales status. When you add Invokana to other drugs approved in the past few years, including the promising TNF-alpha inhibitor Simponi and prostate cancer drug Zytiga, Johnson & Johnson (NYSE:JNJ) has the potential to lift the success of its newer drugs immensely in the next year.
Yet J&J isn’t satisfied with what it already has. Last week, the company joined with Pharmacyclics, Inc. (NASDAQ:PCYC) to seek approval for their lymphoma drug ibrutinib. J&J will get a 50% share of any profit from the venture, and J&J cited a Piper Jaffray estimate that just one of its indications could produce sales of more than $4 billion.